Network meta-analysis of 28 RCTs (13,312 participants) in moderate-to-severe allergic rhinitis: anti-IL-4Rα therapy ranked best for nasal symptoms, then anti-IgE and allergen immunotherapy, above all pharmacotherapies; biologics and AIT did not raise adverse events vs placebo.
Meta-analysisn = 13,312
Zhang et al. Efficacy and Safety of Biologics, Allergen Immunotherapy, and Pharmacotherapies for Moderate-to-Severe Allergic Rhinitis: A Network Meta-Analysis